Published date:Dec 20 2024

Journal Title: Advances in Applied Nano-Bio Technologies

Issue title: Advances in Applied Nano-Bio Technologies: Volume 5 Issue 4

Pages:26 - 38

DOI: 10.18502/aanbt.v5i4.17959

Mohadeseh Parhizkarist_m_parhizkari@azad.ac.irDepartment of Biomedical Engineering, South Tehran Branch, Islamic Azad University, Tehran

This paper investigates the role of gold nanoparticles (GNPs) in cancer diagnosis and treatment from a biometric perspective. Gold nanoparticles are recognized as crucial tools in biomedicine due to their unique properties, including controllable size, chemical stability, and the ability to conjugate with various biomolecules. This study employs data from the Web of Science to conduct a biometric analysis of related articles, examining research trends, scientific collaborations, and practical applications of GNPs in cancer diagnosis and treatment. The findings indicate that GNPs can be used as contrast agents in medical imaging techniques such as CT and MRI, enabling early cancer detection through their ability to target cancer cells. Additionally, GNPs can serve as drug carriers to deliver anti-cancer drugs precisely to target cells, enhancing treatment efficacy while minimizing unwanted side effects. The advantages of GNPs over other nanoparticles, such as high chemical stability and lower toxicity, are also highlighted. Despite significant advancements, further research is needed to understand molecular mechanisms, evaluate long-term effects, and improve GNP production methods. The results of this study demonstrate that gold nanoparticles have a high potential for improving cancer diagnosis and treatment, thereby contributing to the betterment of patient quality of life.

Keywords: Nanoparticles, Oncological Diagnostics, Biomolecular Markers

[1] E. C. Dreaden, M. A. Mackey, X. Huang, B. Kang and M. A. El-Sayed, Chemical Society Reviews 40 (7), 3391-3404 (2011).

[2] S. Jain, D. Hirst and J. O’Sullivan, The British journal of radiology 85 (1010), 101-113 (2012).

[3] I. H. El-Sayed, X. Huang and M. A. El-Sayed, Cancer letters 239 (1), 129-135 (2006).

[4] X. Huang, P. K. Jain, I. H. El-Sayed and M. A. El-Sayed, Lasers in medical science 23, 217-228 (2008).

[5] M. Rai, A. Yadav and A. Gade, Biotechnology advances 27 (1), 76-83 (2009).

[6] S. N. Abootalebi, S. M. Mousavi, S. A. Hashemi, E. Shorafa, N. Omidifar and A. Gholami, Journal of Nanomaterials, 2021, 6676555 (2021).

[7] Y.-S. Chen, Y.-C. Hung, I. Liau and G. S. Huang, Nanoscale research letters 4, 858-864 (2009).

[8] Y.-X. J. Wang, S. M. Hussain and G. P. Krestin, European radiology 11 (11), 2319-2331 (2001).

[9] A. K. Gupta and M. Gupta, biomaterials 26 (18), 3995-4021 (2005).

[10] X. Gao, Y. Cui, R. M. Levenson, L. W. Chung and S. Nie, Nature biotechnology 22 (8), 969-976 (2004).

[11] A. M. Derfus, W. C. Chan and S. N. Bhatia, Nano letters 4 (1), 11-18 (2004).

[12] A. M. Alkilany and C. J. Murphy, Journal of nanoparticle research 12, 2313-2333 (2010).

[13] N. Khlebtsov and L. Dykman, Chemical Society Reviews 40 (3), 1647-1671 (2011).

[14] J. Xie, S. Lee and X. Chen, Advanced drug delivery reviews 62 (11), 1064-1079 (2010).

[15] M. E. Falagas, E. I. Pitsouni, G. A. Malietzis and G. Pappas, The FASEB journal 22 (2), 338-342 (2008).

[16] D. M. Powers, arXiv preprint arXiv:2010.16061 (2020).

[17] N. Van Eck and L. Waltman, scientometrics 84 (2), 523-538 (2010).

[18] H. Small, Journal of the American Society for information Science 24 (4), 265-269 (1973).

[19] M. Aria and C. Cuccurullo, Journal of informetrics 11 (4), 959-975 (2017).

[20] M. E. Newman, Proceedings of the national academy of sciences 101 (suppl_1), 5200-5205 (2004).